Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: Neuropharmacology. 2012 Jul 15;64:348–356. doi: 10.1016/j.neuropharm.2012.07.016

Fig. 4.

Fig. 4

Effects of nACh receptor antagonist treatments on the amelioration of PPI deficits in DAT KO mice by nicotine. Although DAT KO mice treated with saline and saline (sal–sal) displayed significantly reduced PPI compared with WT mice treated with saline and saline (sal–sal), saline and nicotine 1 mg/kg (sal–Nic1) treatments significantly reversed PPI deficits in DAT KO mice at pp12 dB. Pretreatment with mecamylamine, 10 mg/kg (MCA10) or methyllycaconitine, 5 mg/kg (MLA5) significantly antagonized the recovery of PPI by nicotine in DAT KO mice. %PPI values represent mean ± SEM. ***p < 0.001 compared with WT sal–sal; #p < 0.01 compared with DAT KO sal–sal pp12 dB; $p < 0.05 compared with DAT KO sal–Nic1 + MCA10–Nic1 group, and DAT KO sal–Nic1 + MLA5–Nic1 group. N = 11–15 per treatment condition (male N = 5–8, female N = 6–8).